-
MDA 2024: Myotonic dystrophy type 1 reverses with AOC 1001
Long-term treatment with AOC 1001 continues to be safe and may reverse the progression of
-
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
RegenXBio shared additional interim data from their Phase 1/2 AAV micro-dystrophin gene therapy clinical trial
-
REGENXBIO Shares New Positive Initial Efficacy Data From AFFINITY DUCHENNE Trial
REGENXBIO Inc. has shared an update on the Phase I/II AFFINITY DUCHENNE® trial of RGX-202
-
PPMD Celebrates 30th Anniversary and Three Decades of Progress with Annual Advocacy Conference
Over the past three decades, PPMD has driven Congress to enact legislation that has transformed federal
-
PPMD Hosts Town Hall on Clinical Trials During 2024 Advocacy Conference
The PPMD Town Hall on Clinical Trials, taking place on Monday, March 4th during PPMD’s
-
A blessing in disguise: What has my FSHD given me?
I’m reading “Eyes to the Wind: A Memoir of Love and Death, Hope and Resistance”
-
5 things I didn’t anticipate about caring for teens with Duchenne MD
Life is lived in seasons, at least here in Nebraska, where we experience all four
-
LGMD scientific workshop gathers experts to tackle unmet needs
Patients and experts in limb-girdle muscular dystrophy (LGMD), along with drug developers, community leaders, and
-
15th Annual Champions to CureDuchenne Returns to The University of Texas Golf Club on April 6 to Find a Cure for Duchenne Muscular Dystrophy
“Disco For Duchenne” Gala Features Dancing, Drinks, a Culinary Experience and More to Help Advance
-
CureDuchenne Webinar with Dyne Therapeutics | Advancing the Promise of FORCE to Deliver for Patients
Dyne Therapeutics will present initial clinical data, first released on January 3rd, 2024, from the
